DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Phil Noble - 3 Maggie Fick - 3 Danilo Masoni - 2 NOVO.B - 1 Scott Olson - 1 Eli Lilly - 1 Nordisk's Wegovy - 1 Eli Lilly's Zepbound - 1
Top related locs:
Macclesfield London U.S England Bengaluru Britain Madrid Chicago , Illinois
Top related orgs:
AstraZeneca - 4 REUTERS - 3 Thomson - 3 European Society for Medical - 2 New - 1 Halstead Pharmacy - 1 Getty - 1 Novo Nordisk - 1

Search resuls for: "Macclesfield"


8 mentions found


☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
  + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com   time to read: +10 min
Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield
☆ We quit our jobs in TV to start a coffee shop. When we decided to do it on a boat, we had no idea what we were in for.
  + stars: | 2023-11-24 | by ( Aimee Pearcy | ) www.businessinsider.com   time to read: +7 min
Joanna and Victor Gould, both 35, quit their jobs to open a coffee shop on a boat. Holly the Cafe Boat Joanna GouldWe faced a lot of challenges opening our boat cafeIn 2018, we were feeling exhausted from our jobs as freelance television editors. We bought her and decided to name her "Holly the Cafe Boat." Both our cafe boat and the boat we lived on had a continuous cruiser license, which meant we had to move them both every couple of weeks. Serving customers from Holly the Cafe Boat.
Persons: Joanna, Victor Gould, —, we'd, We'd, we've, we're, Holly, Joanna Gould, herder, they'd, We've, We're Organizations: YouTube, Service Locations: Macclesfield, England
☆ AstraZeneca ups profit outlook on strong cancer drugs demand
  + stars: | 2023-11-09 | by ( Maggie Fick Eva Mathews | Maggie Fick | Eva Mathews | ) www.reuters.com   time to read: +3 min
It also expects total revenue to increase by a mid single-digit percentage, compared with low-to-mid single-digit growth previously. For the third consecutive quarter, strong sales of AstraZeneca's blockbuster cancer treatments and healthy demand for its drugs in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy. The results add to a string of strong quarters for Britain's biggest company by market capitalisation - worth 159 billion pounds ($195 billion) - bolstered by a strong pipeline of drugs. It said that in the first nine months of 2023, nine medicines delivered more than $1 billion in revenue. Excluding sales of its COVID-19 products, third-quarter sales rose 12% to $2.96 billion in emerging markets on a constant currency basis.
Persons: Phil Noble, China's, Maggie Fick, Eva Mathews, Nivedita Bhattacharjee, Mark Potter Organizations: AstraZeneca, REUTERS, Britain's, Thomson Locations: Macclesfield, England, China, London, Swedish, Bengaluru
☆ AstraZeneca shares fall as abstract for lung cancer trial data disappoints
  + stars: | 2023-10-18 | by ( ) www.reuters.com   time to read: 1 min
A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after the publication of an abstract on its experimental precision drug's use in lung cancer in a late-stage trial disappointed some analysts. The abstract was published ahead the European Society for Medical Oncology's (ESMO) congress that kicks off in Madrid on Friday. By 1219 GMT, AstraZeneca shares were dwon 3.7% in London, while the broader STOXX Health Care (.SXDP)index was off 1%. Reporting by Danilo Masoni and Maggie FickOur Standards: The Thomson Reuters Trust Principles.
Persons: Phil Noble, Danilo Masoni, Maggie Fick Organizations: AstraZeneca, REUTERS, European Society for Medical, Thomson Locations: Macclesfield, Britain, Madrid, London
☆ AstraZeneca shares fall as lung cancer drug trial data abstract disappoints
  + stars: | 2023-10-18 | by ( ) www.reuters.com   time to read: +2 min
REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after a data abstract on its experimental precision drug's use in lung cancer patients in a late-stage trial disappointed some analysts. Fernandez added that progression-free survival in lung cancer patients came in below expectations. Barclays analyst Emily Field also said in a note that safety looked better than expected for lung cancer patients and the data abstracts were "collectively positive" for AstraZeneca. London-listed shares of AstraZeneca were down 3.7% at 1219 GMT, while the broader STOXX Health Care (.SXDP) index was off 1%. Shares of AstraZeneca's Japanese partner Daiichi Sankyo (4568.T), which is jointly developing the cancer drug, closed 4.6% lower on Tuesday.
Persons: Phil Noble, datopotamab deruxtecan, Jefferies, Stephen Barker, Barker, Seamus Fernandez, Fernandez, Emily Field, GSK's, Danilo Masoni, Maggie Fick, Bhanvi, Shinjini Organizations: AstraZeneca, REUTERS, European Society for Medical, Friday, Guggeinheim, Barclays, AstraZeneca ., Thomson Locations: Macclesfield, Britain, Madrid, AstraZeneca . London, U.S, Milan, London, Bengaluru
☆ U.S. FDA panel to review expanded use of Merck-AstraZeneca's cancer drug
  + stars: | 2023-03-02 | by ( ) www.reuters.com   time to read: +2 min
The U.S. Food and Drug Administration's (FDA) committee is scheduled to meet on April 28. The companies' are seeking approval of the drug Lynparza in combination with other medications – abiraterone and prednisone or prednisolone – for the treatment of a type of treatment-resistant prostate cancer in adult patients. Lynparza was approved in March last year by the FDA as a treatment for patients with early-stage breast cancer with certain mutations. The drug is also approved in the United States as a standalone treatment for another form of prostate cancer. Prostate cancer is the most common form of cancer among men in the United States with about 288,300 new cases of prostate cancer in 2023, according to the American Cancer Society’s estimates.
☆ Government gives green light to independent regulator for English game
  + stars: | 2023-02-22 | by ( Martyn Herman | ) www.reuters.com   time to read: +5 min
Once made law, the Government says the independent regulator would have statutory powers to license and sanction clubs, oversee the financial sustainability of the game and prevent unscrupulous owners buying clubs. It would also have the power to prevent English clubs joining breakaway competitions such as the European Super League which six Premier League clubs signalled their intent to join in 2021 before abandoning plans after a fans' backlash. Although the Premier League, launched in 1992, has been an unprecedented financial success, lower down the English pyramid the situation has been grim. Reacting to the publication of the white paper, Derby owner David Clowes said: "Derby County stared extinction in the face for far too long. The Government says the independent regulator would have targeted powers as a "last resort" to facilitate agreement on the redistribution of funds.
☆ AstraZeneca lifts 2022 earnings outlook as cancer drugs boost results
  + stars: | 2022-11-10 | by ( Natalie Grover | ) www.reuters.com   time to read: +4 min
AstraZeneca is seen as a bellwether for the pharmaceutical sector in China, which accounted for about 16% of the company's total revenue last year. Sales in China have been hurt by lower drug prices while COVID lockdown measures have kept some patients from being diagnosed and seeking care. Better-than-expected sales of AstraZeneca's cancer medicines, including Tagrisso, Imfinzi and Enhertu, helped the company's quarterly revenue beat, with sales of its broader oncology portfolio rising 24%. But global sales of the company's COVID therapy, Evusheld, have steadily grown, partially offsetting the rapid decline in COVID vaccine sales. Evusheld continues to demonstrate strong efficacy but there are a couple of variants that are resistant to it, Soriot said.
0 next >>
Total: 8